Equities research analysts forecast that Puma Biotechnology, Inc. (NASDAQ:PBYI) will announce sales of $53.46 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Puma Biotechnology’s earnings. The highest sales estimate is $53.56 million and the lowest is $53.37 million. Puma Biotechnology reported sales of $50.80 million in the same quarter last year, which suggests a positive year over year growth rate of 5.2%. The business is scheduled to report its next quarterly earnings report on Thursday, November 4th.
On average, analysts expect that Puma Biotechnology will report full year sales of $266.99 million for the current fiscal year, with estimates ranging from $265.11 million to $268.88 million. For the next financial year, analysts anticipate that the company will report sales of $273.57 million, with estimates ranging from $244.19 million to $302.94 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Puma Biotechnology.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.18. Puma Biotechnology had a negative return on equity of 355.42% and a negative net margin of 13.77%. The company had revenue of $53.40 million for the quarter, compared to analysts’ expectations of $51.01 million.
In other Puma Biotechnology news, CEO Alan H. Auerbach sold 5,332 shares of Puma Biotechnology stock in a transaction that occurred on Friday, July 2nd. The stock was sold at an average price of $8.84, for a total value of $47,134.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 11,182 shares of company stock worth $93,217. 19.50% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PBYI. O Shaughnessy Asset Management LLC bought a new stake in shares of Puma Biotechnology during the second quarter valued at approximately $46,000. E Fund Management Co. Ltd. bought a new stake in shares of Puma Biotechnology during the first quarter valued at approximately $48,000. Lazard Asset Management LLC bought a new stake in shares of Puma Biotechnology during the second quarter valued at approximately $64,000. Royal Bank of Canada grew its holdings in Puma Biotechnology by 82.2% during the first quarter. Royal Bank of Canada now owns 9,206 shares of the biopharmaceutical company’s stock worth $89,000 after buying an additional 4,153 shares in the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in Puma Biotechnology during the second quarter worth $101,000. Hedge funds and other institutional investors own 85.05% of the company’s stock.
Puma Biotechnology stock traded up $0.33 during midday trading on Friday, reaching $7.15. The company’s stock had a trading volume of 3,523 shares, compared to its average volume of 370,700. Puma Biotechnology has a 52 week low of $6.48 and a 52 week high of $14.14. The company has a current ratio of 1.22, a quick ratio of 1.16 and a debt-to-equity ratio of 2.33. The business has a 50-day moving average price of $7.31 and a 200-day moving average price of $9.04. The stock has a market cap of $291.57 million, a PE ratio of -7.93 and a beta of 1.13.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.